Somprasong Liamsombut

Somprasong Liamsombut

Auto-generated profile, based on publicly available information

Somprasong Liamsombut

Division of Sleep Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2022 in Journal of Clinical Virology
Verified
Journal Article
Closed access
GSGasit Saksirisampant
Gasit Saksirisampant
TKTheerasuk Kawamatawong
Theerasuk Kawamatawong
KPKawin Promsombat
Kawin Promsombat
WSWarawut Sukkasem
Warawut Sukkasem
SLSomprasong Liamsombut
Somprasong Liamsombut
JBJackrapong Bruminhent
Jackrapong Bruminhent

10 April 2025 in CNS Drugs
Verified
Journal Article
Open access
PDF file
PTPongsakorn Tanayapong
Pongsakorn Tanayapong
VTVisasiri Tantrakul
Visasiri Tantrakul
SLSomprasong Liamsombut
Somprasong Liamsombut
SSSukanya Siriyotha
Sukanya Siriyotha
GMGareth McKay
Gareth McKay
ATAmmarin Thakkinstian
Ammarin Thakkinstian
Background and objectives Residual sleepiness can occur in adult patients with obstructive sleep apnea (OSA) despite adequate treatment with continuous positive airway pressure (CPAP). Various wake-promoting agents (WPAs) have been shown to reduce residual sleepiness in CPAP-treated patients with OSA. This systematic review and network meta-analysis aimed to compare the efficacy and safety of WPAs in this setting. Methods We searched MEDLINE, Scopus, and ClinicalTrials.gov up to 9 January 2025 for randomized controlled trials (RCTs) examining WPAs for treating sleepiness in patients with OSA. Included were all RCTs that explored the efficacy and/or safety of any approved WPAs (i.e., modafinil, armodafinil, solriamfetol, or pitolisant) in patients with OSA (aged \(\ge\) 18 years) treated with CPAP but who are still sleepy [Epworth sleepiness scale (ESS) score ≥10]. Studies that were conducted in patients whose comorbidities cause daytime somnolence [i.e., psychiatric conditions (other than depression), other sleep disorders, medical or surgical conditions], open label extension studies, and studies published in a language other than English were excluded. The primary outcomes included ESS, maintenance of wakefulness test (MWT), and adverse events. Two authors independently assessed the risk of bias using the revised Cochrane risk-of-bias tool for randomized trials 2.0. Results In total, 14 RCTs studying four WPAs (total N = 2969) including modafinil (six RCTs; 200–400 mg/day), armodafinil (four RCTs; 150–250mg/day), solriamfetol (two RCTs; 37.5–300 mg/day), and pitolisant (two RCTs; 5–40 mg/day) were included. Solriamfetol, modafinil, and armodafinil were efficacious in reducing subjective sleepiness as measured by ESS [mean difference (95% confidence interval) at \(\le\) 4 weeks: −3.84 (−5.60, −2.07), −2.44 (−3.38, −1.49), and −2.41 (−3.60, −1.21) for solriamfetol, modafinil, and armodafinil, respectively; at > 4 weeks: −4.11 (−6.14, −2.08), −2.88 (−3.85, −1.91), −2.46 (−3.68, −1.24) for solriamfetol, armodafinil, and modafinil, respectively] and clinical global impression of change, as well as the objective MWT [at \(\le\) 4 weeks: 11.66 min (9.70, 13.61), 3.61 min (2.48, 4.73), and 2.52 min (1.27, 3.76) for solriamfetol, modafinil, and armodafinil, respectively; at > 4 weeks: 10.34 min (4.16, 16.52) for solriamfetol]. Pitolisant showed later improvements in ESS [at > 4 weeks: −2.70 (−3.66, −1.73)], with limited data on MWT. Sensitivity analyses restricted to U.S. Food and Drug Administration-approved solriamfetol dosages (37.5–150 mg/day) still showed higher efficacy, but lower anxiety risk. Conclusions Among all WPAs, solriamfetol demonstrated the highest efficacy on ESS and MWT, with the latter being significant. Modafinil demonstrated the best clinician impression, albeit not statistically significant. All four WPAs were associated with a low risk of serious or adverse events. Registration PROSPERO registration number, CRD42022359237

25 April 2022 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
SLSomprasong Liamsombut
Somprasong Liamsombut
CPCherrin Pomsoong
Cherrin Pomsoong
CKChaninan Kositkuljorn
Chaninan Kositkuljorn
KLKanchana Leerunyakul
Kanchana Leerunyakul
VTVisasiri Tantrakul
Visasiri Tantrakul
PSPoonkiat Suchonwanit
Poonkiat Suchonwanit

27 May 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
KSKanyarat Susantitapong
Kanyarat Susantitapong
PDPitchaya Dilokpattanamongkol
Pitchaya Dilokpattanamongkol
YSYuda Sutherasan
Yuda Sutherasan
SLSomprasong Liamsombut
Somprasong Liamsombut
CSChuthamanee Suthisisang
Chuthamanee Suthisisang
Sleep deprivation is a prevalent problem in critically ill patients, which leads to delayed recovery and delirium. Slow‐wave sleep (SWS) is essential to energy restoration, tissue repair, and immune system strengthening. This study aimed to investigate the effects of gabapentin on SWS in critically ill patients. We performed a prospective open‐label randomized controlled study to compare SWS and the clinical outcomes of gabapentin versus a control intervention in critically ill adult patients admitted to the intensive care unit (ICU) within 24 h. The patients' characteristics and sleep‐related outcomes were recorded. The sleep‐related outcomes, namely, bispectral analysis (BIS), the Richards‐Campbell Sleep Questionnaire (RCSQ), and insulin‐like growth factor‐1 (IGF‐1) levels, were evaluated. Furthermore, clinical outcomes and safety were assessed. Sixty patients from 348 cases were eligible for randomization. On day 3 of the study, patients in the gabapentin group had significantly increased SWS (66.79 vs. 0.00 min; p < 0.001), total sleep time (TST) (331.39 vs. 46.16 min; p = 0.001), RCSQ score (55.05 ± 20.18 vs. 32.80 ± 15.31; p < 0.001), and IGF‐1 concentrations (84.33 ± 12.40 vs. 44.00 ± 10.20 ng/mL, p < 0.001) compared with the control group. Improvements in clinical outcomes, such as delirium, ICU‐free days, and mechanical ventilator‐free days, were observed; however, these differences did not reach statistically significant. Gabapentin at bedtime increased SWS, TST, and IGF‐1 concentrations in critically ill patients. This regimen might be beneficial to critically ill patients for improving their sleep quality.

1 August 2021 in Sleep Medicine
Verified
Journal Article
Closed access
SLS. Liamsombut
S. Liamsombut
RKRoop K Kaw
Roop K Kaw
LWL. Wang
L. Wang
JBJames Bena
James Bena
NAN. Andrews
N. Andrews
NFN. Foldvary-Schaefer
N. Foldvary-Schaefer